Therefore, MOG1, delivered by gene therapy, may be used as an effective tool to treat patients with BrS and sick sinus syndrome with SCN5A/Nav1.5 mutations and other cardiac diseases with reduced INa. The gene discussed is SCN5A; the disease is heart disorder.